A phase I trial of cyclosporine for hospitalized patients with COVID-19 is a research paper published in JCI Insight (2022). On theSindex it has a DataRank of 0.766. It has been cited 24 times, with 24 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.483
From this paper's citation signal
Citation Network Contribution
0.283
From 15 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 24 citers.
Center for Cellular Immunotherapies - internal funding from the University of Pennsylvania
Grant: n/a
Center for Cellular Immunotherapies, University of Pennsylvania
Grant: no funding number (internal funding)
MeSH Terms
Keywords